These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 19417770)
1. Novel strategies for controlling Streptococcus pyogenes infection and associated diseases: from potential peptide vaccines to antibody immunotherapy. Pandey M; Sekuloski S; Batzloff MR Immunol Cell Biol; 2009 Jul; 87(5):391-9. PubMed ID: 19417770 [TBL] [Abstract][Full Text] [Related]
2. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from Ozberk V; Reynolds S; Huo Y; Calcutt A; Eskandari S; Dooley J; Mills JL; Rasmussen IS; Dietrich J; Pandey M; Good MF mBio; 2021 Feb; 12(1):. PubMed ID: 33622722 [TBL] [Abstract][Full Text] [Related]
3. Vaccine development for group A streptococcus infections and associated disease. Batzloff MR; Sriprakash KS; Good MF Curr Drug Targets; 2004 Jan; 5(1):57-69. PubMed ID: 14738218 [TBL] [Abstract][Full Text] [Related]
4. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus. Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510 [TBL] [Abstract][Full Text] [Related]
5. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein. Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479 [TBL] [Abstract][Full Text] [Related]
6. Lipid core peptide technology and group A streptococcal vaccine delivery. Olive C; Batzloff MR; Toth I Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197. Caro-Aguilar I; Ottinger E; Hepler RW; Nahas DD; Wu C; Good MF; Batzloff M; Joyce JG; Heinrichs JH; Skinner JM Hum Vaccin Immunother; 2013 Mar; 9(3):488-96. PubMed ID: 23249976 [TBL] [Abstract][Full Text] [Related]
8. Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate. Batzloff MR; Fane A; Gorton D; Pandey M; Rivera-Hernandez T; Calcutt A; Yeung G; Hartas J; Johnson L; Rush CM; McCarthy J; Ketheesan N; Good MF Hum Vaccin Immunother; 2016 Dec; 12(12):3089-3096. PubMed ID: 27541593 [TBL] [Abstract][Full Text] [Related]
10. Vaccination with Streptococcus pyogenes nuclease A stimulates a high antibody response but no protective immunity in a mouse model of infection. Radcliff FJ; Fraser JD; Proft T Med Microbiol Immunol; 2015 Apr; 204(2):185-91. PubMed ID: 25119670 [TBL] [Abstract][Full Text] [Related]
11. Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines. Reynolds S; Pandey M; Dooley J; Calcutt A; Batzloff M; Ozberk V; Mills JL; Good M Sci Rep; 2021 Jan; 11(1):127. PubMed ID: 33420258 [TBL] [Abstract][Full Text] [Related]
12. A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes. Bi S; Xu M; Zhou Y; Xing X; Shen A; Wang B mBio; 2019 Nov; 10(6):. PubMed ID: 31772056 [TBL] [Abstract][Full Text] [Related]
13. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480 [TBL] [Abstract][Full Text] [Related]
14. The quest for GAS vaccine. Pandey M; Good MF Oncotarget; 2015 Oct; 6(33):34063-4. PubMed ID: 26485764 [No Abstract] [Full Text] [Related]
15. Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection. Schulze K; Ebensen T; Chandrudu S; Skwarczynski M; Toth I; Olive C; Guzman CA Nanomedicine; 2017 Nov; 13(8):2463-2474. PubMed ID: 28887213 [TBL] [Abstract][Full Text] [Related]
16. Adapting immunity with subunit vaccines: case studies with group A Streptococcus and malaria. Good MF; Xu H; Batzloff M Int J Parasitol; 2002 May; 32(5):575-80. PubMed ID: 11943230 [TBL] [Abstract][Full Text] [Related]
17. Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components. Abdel-Aal AB; Zaman M; Fujita Y; Batzloff MR; Good MF; Toth I J Med Chem; 2010 Nov; 53(22):8041-6. PubMed ID: 21028828 [TBL] [Abstract][Full Text] [Related]
18. Development of Group A streptococcal vaccines: an unmet global health need. Sheel M; Moreland NJ; Fraser JD; Carapetis J Expert Rev Vaccines; 2016; 15(2):227-38. PubMed ID: 26559880 [TBL] [Abstract][Full Text] [Related]
19. Active and passive immunizations with the streptococcal esterase Sse protect mice against subcutaneous infection with group A streptococci. Liu M; Zhu H; Zhang J; Lei B Infect Immun; 2007 Jul; 75(7):3651-7. PubMed ID: 17502395 [TBL] [Abstract][Full Text] [Related]
20. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci. Good MF; Pandey M; Batzloff MR; Tyrrell GJ Expert Rev Vaccines; 2015; 14(11):1459-70. PubMed ID: 26485214 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]